New Leaf Venture Partners leads Series B round for Unum Therapeutics

Cambridge, Massachusetts-based Unum Therapeutics, a developer of antibody-directed cellular immunotherapy, has closed $65 million in Series B funding. New Leaf Venture Partners led the round with participation from other investors that included Brace Pharma Capital, Cowen Private Investments, Novo A/S, Sabby Management LLC, Wellington Management Company LLP, Fidelity Biosciences, Atlas Venture and Sanofi-Genzyme BioVentures. In addition to the funding, Dr. Liam Ratcliffe, managing director at New Leaf Venture Partners, has been added to Unum’s board of directors.

142 Views

Regenxbio racks up $70.5 mln Series D

Rockville, Maryland-based Regenxbio, a gene therapy-focused biotech company, has closed $70.5 million in Series D funding. Vivo Capital, Venrock and Brookside Capital led the round with participation from other investors that included Janus Capital Management LLC, Perceptive Advisors LLC, Tourbillon Global Ventures, Sectoral Asset Management, Cormorant Asset Management LLC, Foresite Capital Management, Deerfield Management and Fidelity Biosciences. Chardan Capital Markets LLC was the placement agent.

206 Views

Denali launches with $217 mln

Denali Therapeutics Inc, a developer of treatments for neurodegenerative diseases, has launched with a $217 million investment commitment. The investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund.

118 Views

Precision BioSciences raises $25.6 mln

Precision BioScience said Monday it closed a $25.6 million Series A round led by venBIO. Fidelity Biosciences, Amgen Ventures, Baxter Ventures, Osage University Partners, the Longevity Fund, and two well-known public market investors also participated. Research Triangle Park, North Carolina-based Precision BioSciences is a genome editing company.

Symbiomix Therapeutics racks up $41 mln

Newark, New Jersey-based Symbiomix Therapeutics, which develops medicines for serious women’s health infections, has received the final tranche of its $41 million Series A round. The investors included OrbiMed, Fidelity BioSciences and HBM Partners.

181 Views

Dimension Therapeutics nets $65 mln Series B

Cambridge, Massachusetts-based Dimension Therapeutics Inc, which is focused on developing treatments for liver disorders, has closed $65 million in Series B funding. New Leaf Venture Partners led the round with participation from other investors that included Jennison Associates (on behalf of investors), Partner Fund Management, RA Capital Management, Rock Springs Capital, Tourbillon Global Ventures, Fidelity Biosciences and OrbiMed. In addition to the funding, Dr. Mike Dybbs, a partner at New Leaf Venture Partners, has been added to Dimension’s board of directors.

227 Views

Quartet Health snags $7 mln

New York-based tech company Quartet Health has secured $7 million in funding. Annie Lamont of Oak HC/FT led the round with participation from other investors that included participation from Shulman Ventures, Fidelity Biosciences and Polaris Partners. In conjunction with the funding, Lamont has been added to Quartet Health’s board of directors.

Semma Therapeutics nets $44 mln

Cambridge, Massachusetts-based Semma Therapeutics, a developer of cell therapy for Type 1 diabetes, has secured $44 million in Series A funding. MPM Capital led the round with participation from Fidelity Biosciences, ARCH Venture Partners and Medtronic. Also, the company has named Stephen Oesterle, senior vice president for medicine and technology at Medtronic, as a board observer.

145 Views

TraceLink rakes in $20 mln

Wakefield, Massachusetts-based TraceLink, a provider of patient safety solutions for life sciences, has closed $20 million in funding. Volition Capital led the round with participation from other investors that included Fidelity Biosciences and FirstMark Capital.

Innovent Biologics grabs $100 mln Series C

Chinese biopharmaceutical firm Innovent Biologics has closed $100 million in Series C funding. Legend Capital led the round with participation from other backers that included Temasek, Fidelity Biosciences, Fidelity Growth Partners Asia, Lilly Asia Ventures and Frontline Bioventures.

158 Views

Iora Health picks up $28 mln

Cambridge, Massachusetts-based healthcare firm Iora Health has raised $28 million in Series C funding. The investors included Foundation Medical Partners, Rice Management Company, GE Ventures, Khosla Ventures, .406 Ventures, Fidelity Biosciences and Polaris Partners.

136 Views

Regenxbio picks up $30 mln Series C

Regenxbio, a gene therapy biotech firm, has closed $30 million in Series C funding. Venrock and Brookside Capital led the round with participation from others investors that included Deerfield Management, FoxKiser and Fidelity BioSciences. Also, Camille Samuels, a partner at Venrock and Michael Gelman have been added to Regenxbio’s board of directors.

110 Views

Surface Oncology attracts $35 mln Series A

Surface Oncology has secured $35 million in Series A funding. Atlas Venture, Fidelity Biosciences, Lilly Ventures and New Enterprise Associates led the round with participation from other investors that included Amgen Ventures and Novartis Institute for Biomedical Research. In addition to the funding, Dr. Elliott Sigal, former head of R&D at Bristol Myers Squibb, has been added to the company’s scientific advisory board. Based in Cambridge, Mass., Surface Oncology is a developer of next-generation cancer immunotherapies.

152 Views

Polaris, Fidelity Biosciences invest $10 mln in Novaerus

Polaris Partners and Fidelity Biosciences have invested $10 million in Novaerus, which works on infection prevention products for nursing homes and assisted living facilities in the U.S. and Europe. Novaerus received a previous investment from Oyster Capital Partners, which will continue to be the majority shareholder in the company.

178 Views

Blueprint Medicines ropes in $50 mln

Blueprint Medicines has raised $50 million in Series C funding. Partner Fund Management led the round with participation from other investors that included Wellington Management Company, RA Capital, Tavistock Life Sciences, Perceptive Advisors, Sabby Capital, Cowen Investments, Redmile Group, Fidelity Biosciences and Third Rock Ventures. Based in Cambridge, Mass., Blueprint Medicines is a developer of kinase inhibitors for genomically defined cancers.

195 Views

Unum Therapeutics scores $12 mln Series A

Unum Therapeutics has received $12 million in Series A funding. Fidelity Biosciences and Atlas Venture led the round with participation from Sanofi-Genzyme BioVentures. Headquartered in Cambridge, Mass., Unum Therapeutics is developing cellular immunotherapy to treat cancer.

159 Views

Avidity NanoMedicines racks up $6 mln

Avidity NanoMedicines has secured $6 million in convertible note financing. Fidelity Biosciences and TPG Biotech co-led the round. Other investors included Brace Pharmaceuticals, Partner Fund Management and return backer Alethea Capital Management. In addition to the funding, Ben Auspitz from Fidelity Biosciences and Dr. Eran Nadav from TPG Biotech, will be added to Avidity’s board as observers. Based in La Jolla, Calif., Avidity is a maker of drugs that include antibody-siRNA complexes.

PE HUB Community

Join the 12519 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget